Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Di Lauro, Luigi ^a   Giacinti, Laura ^b   Arena, Maria Grazia ^c   Sergi, Domenico ^a   Fattoruso, Silvia Ileana ^a   Giannarelli, Diana ^d   Lopez, Massimo ^a  

^a Institute for Cancer Research   (Italy)

^b San Giuseppe Hospital   (Italy)

^c Toraldo Hospital   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IRINOTECAN; OXALIPLATIN; PALONOSETRON; PREDNISONE; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HUMAN; LOWER ESOPHAGUS SPHINCTER ADENOCARCINOMA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; ADENOCARCINOMA; DISEASE FREE SURVIVAL; LOWER ESOPHAGUS SPHINCTER; METASTASIS; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; EPIRUBICIN; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 62849098200     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-34     Document Type: Article

References (17)

1. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. F Kamangar GM Dores WF Anderson, J Clin Oncol 2006 24 2137 2150 10.1200/JCO.2005.05.2308 16682732
2. Estimates of the cancer incidence and mortality in Europe in 2006. J Ferlay P Autier M Boniol M Heanue M Colombet P Boyle, Ann Oncol 2007 18 581 592 10.1093/annonc/mdl498 17287242
3. Chemotherapy in advanced gastric cancer: a systemic review and meta-analysis based on aggregate data. AD Wagner W Grothe J Haerting G Kleber A Grothey WE Fleig, J Clin Oncol 2006 24 2903 2909 10.1200/JCO.2005.05.0245 16782930
4. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. E Van Cutsem C Van de Velde A Roth F Lordick CH Köhne S Cascinu M Aapro, Eur J Cancer 2008 44 182 194 10.1016/j.ejca.2007.11.001 18093827
5. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. C Louvet T André JM Tigaud E Gamelin JY Douillard R Brunet E Francois JH Jacob D Levoir A Taamma P Rougier E Cvitkovic A de Gramont, J Clin Oncol 2002 20 4543 4548 10.1200/JCO.2002.02.021 12454110
6. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. SE Al-Batran A Atmaca S Hegewisch-Becker D Jaeger S Hahnfeld MJ Rummel G Seipelt A Rost J Orth A Knuth E Jaeger, J Clin Oncol 2004 22 658 663 10.1200/JCO.2004.07.042 14966088
7. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. F De Vita M Orditura E Matano R Bianco C Carlomagno S Infusino V Damiano E Simeone MR Diadema E Lieto P Castellano S Pepe S De Placido G Galizia N Di Martino F Ciardiello G Catalano AR Bianco, Br J Cancer 2005 92 1644 1649 10.1038/sj.bjc.6602573 15856038
8. Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. F Lordick S Lorenzen J Stollfuss U Vehling-Kaiser F Kullmann M Hentrich R Zumschlinge H Dietzfelbinger J Thoedtmann M Hennig T Seroneit R Bredenkamp J Duyster C Peschel, Br J Cancer 2005 93 190 194 10.1038/sj.bjc.6602697 16012522
9. A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. YH Park BS Kim BY Ryoo SH Yang, Br J Cancer 2006 94 959 963 10.1038/sj.bjc.6603046 16552439
10. Docetaxel in the treatment of gastric cancer. PC Thuss-Patience A Kretzschmar P Reichardt, Future Oncol 2006 2 603 620 10.2217/14796694.2.5.603 17026452
11. Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. L Di Lauro F Belli MG Arena S Carpano G Paoletti D Giannarelli M Lopez, Ann Oncol 2005 16 1498 1502 10.1093/annonc/mdi281 15956036
12. New guidelines to evaluate the response to treatment in solid tumours. P Therasse SG Arbuck E Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther, J Natl Cancer Inst 2000 92 205 216 10.1093/jnci/92.3.205 10655437
13. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. JP Caussanel F Levi S Brienza JL Misset M Itzhaki R Adam G Milano B Hecquet G Mathè J Natl Cancer Inst 1990 82 1046 1050 10.1093/jnci/82.12.1046 2348469
14. Optimal two-stage designs for phase II clinical trials. R Simon, Control Clin Trials 1989 10 1 10 10.1016/0197-2456(89)90015-9 2702835
15. Capecitabine and oxaliplatin for advanced esophagogastric cancer. D Cunningham N Starling S Rao T Iveson M Nicolson F Coxon G Middleton F Daniel J Oates AR Norman, N Engl J Med 2008 358 36 46 10.1056/NEJMoa073149 18172173
16. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. SE Al-Batran JT Hartmann S Probst H Schmalenberg S Hollerbach R Hofheinz V Rethwisch G Seipelt N Homann G Wilhelm G Schuch J Stoehlmacher HG Derigs S Hegewisch-Becker J Grossmann C Pauligk A Atmaca C Bokemeyer A Knuth E Jäger, J Clin Oncol 2008 26 1435 1442 10.1200/JCO.2007.13.9378 18349393
17. Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents? C Pozzo C Barone, Oncologist 2008 13 794 806 10.1634/theoncologist.2008-0082 18614586